Mental Health Clinics in Wallingford, PA Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Carelink Community Support Services Of Pennsylvania Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 614 W Brookhaven Rd, Wallingford, PA 19086 Phone: 610-874-1119 Fax: 610-565-3801 |
Carelink Community Support Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 920 S Providence Rd, Wallingford, PA 19086 Phone: 610-872-8141 Fax: 610-872-8138 |
Life Turn Healing Center Counselor - Pastoral Medicare: Not Enrolled in Medicare Practice Location: 105 Walnut Rd, Wallingford, PA 19086 Phone: 217-722-8718 |
News Archive
Heart rate variability may increase epilepsy risk
Doctors have long characterized epilepsy as a brain disorder, but researchers at Case Western Reserve University have found that part of the autonomic nervous system functions differently in epilepsy during the absence of seizures.This connection to the involuntary division of the nervous system may have implications for diagnosing and treating the disease and understanding sudden unexpected death in epilepsy
Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger
Dragon Pharmaceutical Inc. announced that based on the receipt of preliminary proxies, the Company believes that it has sufficient votes to approve the Agreement and Plan of Merger by and among Dragon, Chief Respect Limited, Datong Investment Inc., a subsidiary of Chief Respect Limited, and Mr. Yanlin Han.
United BioSource Corporation acquires Abt Bio-Pharma Solutions
Abt Associates announced today the sale of its wholly-owned subsidiary Abt Bio-Pharma Solutions, Inc. to United BioSource Corporation, a global scientific and medical affairs organization that partners with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care technologies.
NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval
Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).
› Verified 6 days ago